
<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>Preclinical Development</title>
  <link rel="stylesheet" href="styles.css" />
</head>
<body>
  <header><h1>Preclinical Development</h1></header>
  <nav><a href="index.html">Back to Home</a></nav>
  <main>
    <section>
      <h2>What is Preclinical Development?</h2>
      <p>Preclinical development is the stage in drug discovery where lead compounds are tested in laboratory and animal models to evaluate their safety, efficacy, pharmacokinetics, and pharmacodynamics before entering human clinical trials.</p>
    </section>

    <section>
      <h2>Basic Concepts</h2>
      <ul>
        <li><strong>In Vitro Studies:</strong> Experiments conducted in cell cultures or biochemical assays to assess activity, toxicity, and mechanism of action.</li>
        <li><strong>In Vivo Studies:</strong> Animal testing to evaluate pharmacokinetics, pharmacodynamics, and systemic effects.</li>
        <li><strong>GLP Compliance:</strong> Good Laboratory Practice standards ensure data integrity and reproducibility.</li>
      </ul>
    </section>

    <section>
      <h2>Safety and Efficacy Testing</h2>
      <ul>
        <li><strong>Toxicology:</strong> Acute, sub-chronic, and chronic toxicity studies in rodents and non-rodents.</li>
        <li><strong>Genotoxicity:</strong> Ames test, micronucleus assay, and chromosomal aberration tests.</li>
        <li><strong>Carcinogenicity:</strong> Long-term studies to assess cancer risk.</li>
        <li><strong>Reproductive Toxicity:</strong> Effects on fertility, embryonic development, and teratogenicity.</li>
        <li><strong>Pharmacokinetics (PK):</strong> Absorption, distribution, metabolism, and excretion profiling.</li>
        <li><strong>Pharmacodynamics (PD):</strong> Mechanism of action and dose-response relationships.</li>
      </ul>
    </section>

    <section>
      <h2>Technologies and Tools</h2>
      <ul>
        <li>Cell-based assays and organoids</li>
        <li>Animal models (mice, rats, dogs, primates)</li>
        <li>Imaging techniques (MRI, PET, CT)</li>
        <li>Bioanalytical methods (LC-MS/MS, ELISA)</li>
        <li>Omics profiling (transcriptomics, proteomics)</li>
        <li>In silico modeling and simulation</li>
      </ul>
    </section>

    <section>
      <h2>Challenges in Preclinical Development</h2>
      <ul>
        <li>Translatability of animal data to humans</li>
        <li>Ethical concerns and animal welfare</li>
        <li>High costs and long timelines</li>
        <li>Regulatory complexity and documentation</li>
        <li>Variability in biological responses</li>
      </ul>
    </section>

    <section>
      <h2>Real-World Examples</h2>
      <ul>
        <li><strong>Monoclonal antibodies:</strong> Preclinical testing in non-human primates for immunogenicity and toxicity.</li>
        <li><strong>Anticancer agents:</strong> Xenograft models to evaluate tumor regression and survival.</li>
        <li><strong>Vaccines:</strong> Immunogenicity and challenge studies in animal models.</li>
      </ul>
    </section>

    <section>
      <h2>Future Directions</h2>
      <ul>
        <li>Use of humanized animal models</li>
        <li>Integration of organ-on-chip and microfluidic systems</li>
        <li>AI-driven predictive toxicology</li>
        <li>Reduction and replacement of animal testing</li>
        <li>Real-time monitoring and wearable biosensors</li>
      </ul>
    </section>
  </main>

  <footer><p>&copy; 2025 Drug Discovery Knowledge Base</p></footer>
</body>
</html>
